Psyence Biomedical Successfully Completes $2 Million Private Placement
Psyence Biomedical Ltd. (NASDAQ: PBM) has successfully closed a private placement aimed at enhancing its financial position.
Details of the Private Placement
This private placement involved the issuance of 1,000,000 common shares and warrants. The purchase price was set at $2.00 per common share or pre-funded warrant equivalent. The total gross proceeds amounted to approximately $2 million before expenses. This capital will be strategically allocated to advance the company's operations.
Common Warrants Offered
Included in the offering were series A and series B common warrants, each allowing purchase of up to 1,000,000 common shares. The series A warrants hold an exercise price of $2.00 and will remain viable for five years, while the series B warrants are effective for two years, providing investors with flexibility and potential upside.
Utilization of Funds
The net proceeds from the offering will be directed toward working capital and general corporate purposes. This strategic move is essential for Psyence as it continues to develop its innovative psilocybin-based therapies.
Role of Placement Agent
H.C. Wainwright & Co. served as the exclusive placement agent for this offering, showcasing their expertise in managing private placement deals.
About Psyence Biomedical Ltd.
Psyence Biomedical Ltd. is pioneering the research and development of nature-derived psilocybin-based psychedelic medicines with a strong focus on mental health care. The unique name “Psyence” blends psychedelics with science, reflecting the firm’s dedication to evidence-based practices in therapeutic innovation.
Commitment to Patient Care
At the heart of Psyence's mission is addressing the pressing needs of patients suffering from mental health disorders, especially in palliative care. By leveraging psilocybin’s potential, the company aims to deliver groundbreaking treatments that can alter patients' lives for the better.
Outlook and Future Endeavors
Psyence’s commitment to developing regulatory-approved treatments highlights its forward-thinking strategy in the rapidly evolving biopharma landscape. Investors are keenly watching the company as it navigates the complexities of clinical development and regulatory scrutiny.
Contact Information for Inquiries
For investor relations or media inquiries, Psyence Biomedical provides dedicated email contacts. General inquiries can be sent to info@psyencebiomed.com. Alternatively, investors can reach out directly via email at jfeffer@lifesciadvisors.com.
Frequently Asked Questions
What is Psyence Biomedical's main focus?
Psyence Biomedical specializes in developing psilocybin-based therapeutic treatments for mental health disorders.
How much money did the company raise?
The company successfully raised approximately $2 million through a private placement.
What types of warrants were issued in the private placement?
Series A and series B common warrants were issued, allowing the purchase of additional shares.
Who acted as the placement agent for the offering?
H.C. Wainwright & Co. served as the exclusive placement agent for this capital raise.
What are the intended uses for the raised funds?
The funds will be used for working capital and general corporate purposes to support ongoing operations.
